More recently, we have shown that non-phosphorylatable mutations of tyrosines 397 and 861 (Y397 and Y861) in endothelial cells have differential effects on tumour angiogenesis [17] and that endothelial cell FAK regulates angiocrine signalling in the control of doxorubicin sensitivity in malignant cells [18]. This evidence concerns the gene PTK2 and neoplasm.